Esperion Therapeutics Announces Proposed Public Offering of Common Stock
Esperion Therapeutics Announces Proposed Public Offering of Common Stock
October 14, 2014
J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the proposed offering.
Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to fund the continued development of ETC-1002 through the anticipated Phase 3 development program, which will include several clinical studies; chemistry, manufacturing and controls (CMC) scale up and supplies development; regulatory compliance and the remainder for working capital and general corporate and administrative expenses.
The securities described may be offered by Esperion pursuant to a shelf
registration statement on Form S-3 (No. 333-197125) including a base
prospectus. The securities may be offered only by means of a prospectus.
A preliminary prospectus supplement related to the offering and a final
prospectus supplement related to the offering will be filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About
Forward Looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities laws,
including statements regarding the therapeutic potential of, and
clinical development plan for, ETC-1002 and statements pertaining to our
expectations regarding the completion and anticipated proceeds of the
proposed public offering. These statements are based on management's
current expectations and accordingly are subject to uncertainty and
changes in circumstances. Actual results could differ materially from
those anticipated due to certain risks and uncertainties including,
without limitation, risks and uncertainties related to fluctuations in
our stock price, changes in market conditions and satisfaction of
customary closing conditions related to the public offering. There can
be no assurance that Esperion will be able to complete the public
offering on the anticipated terms, or at all. Any express or implied
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward-looking statements involve risks and uncertainties that could
cause Esperion's actual results to differ significantly from those
projected, including, without limitation, the risk that positive results
from a clinical study of ETC-1002 may not necessarily be predictive of
the results of future clinical studies, particularly in different or
larger patient populations, or the risk that other unanticipated
developments could interfere with the development (and
commercialization) of ETC-1002, as well as other risks detailed in
Esperion's filings with the
Media:
212.257.6724
efox@w2ogroup.com
Investor:
734.887.3903
mlowe@esperion.com
Source:
News Provided by Acquire Media